CSL Ltd
CSL: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$147.00 | Dtvrx | Vmzpnxjwn |
Demand for CSL Products Persists but Pandemic Constrains Near-Term Supply
Business Strategy and Outlook
CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in production. The plasma sourcing market is currently in short supply, however CSL is well-positioned having invested significantly in plasma collection centres, expanding faster than peers to now own over 30% of collection centres globally.